Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
European Journal of Haematology|November 28, 2015
Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markersJiri Minarik, Zuzana Hermanova, Pavla Petrova, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2011
Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomideMartina Almasi, Sabina Sevcikova, Ondrej Slaby, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2022
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry DataVladimir Maisnar, Ludek Pour, Ivan Spicka, et al.
Scientific Reports|July 20, 2021
Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalitiesEva Kriegova, Regina Fillerova, Jiri Minarik, et al.
Biomedicines|October 27, 2022
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with PlasmacytomasMartin Stork, Sabina Sevcikova, Tomas Jelinek, et al.
Annals of Hematology|April 23, 2023
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysisMartin Stork, Ivan Spicka, Jakub Radocha, et al.
BMC Cancer|April 9, 2025
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma GroupJiri Minarik, Ludek Pour, Vojtech Latal, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
Annals of Hematology|April 3, 2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaEvangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, et al.
Annals of Hematology|August 18, 2025
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysisMartin Stork, Jakub Radocha, Jana Mihalyova, et al.
Pageof 4